Advertisement
Table 1 Patients’ characteristics
| Characteristic | All pts. | Initial diagnosis | PSA relapse | PSA persistence |
|---|---|---|---|---|
| Number | 129 | 20 | 49 | 60 |
| Age (years; median, range) | 72 (47–86) | 76 (53–86) | 74 (50–83) | 69 (47–83) |
| Gleason Score [pts] | ||||
| 6 | 11 (8.5%) | 3 (15%) | 7 (14.3%) | 1 (1.7%) |
| 7a | 27 (20.9%) | 3 (15%) | 19 (38.8%) | 5 (8.3%) |
| 7b | 37 (28.7%) | 6 (30%) | 11 (22.4%) | 20 (33.3%) |
| 8 | 18 (14%) | 3 (15%) | 7 (14.3%) | 8 (13.3%) |
| 9 | 34 (26.4%) | 5 (25%) | 5 (10.2%) | 24 (40.0%) |
| 10 | 2 (1.6%) | – | – | 2 (3.3%) |
| Risk group (D’Amico) [pts] | ||||
| low | 5 (3.9%) | 1 (5.0%) | 3 (6.1%) | 1 (1.7%) |
| intermediate | 21 (16.3%) | 2 (10.0%) | 13 (26.5%) | 6 (10.0%) |
| high | 103 (79.8%) | 17 (85%) | 33 (67.3%) | 53 (88.3%) |
| PSMA PET positive [pts] | 92 (71.3%) | 20 (100%) | 27 (55.1%) | 45 (75%) |
| PSA PRE-PSMA PET [ng/ml] (median/mean, range) | 0.86/6.04 (0.13–150.00) | 12.4/27.28 (0.14–150.0) | 0.49/1.00 (0.15–6.24) | 0.99/3.08 (0.13–39.2) |
| PSA doubling time | ||||
| ≤ 10 months | 81 (74.3%) | – | 21 (42.9%) | 60 (100%) |
| > 10 months | 28 (25.7%) | – | 28 (57.1%) | – |
| ADT at time of PET [pts] | 14 (10.9%) | 2 (10%) | 4 (8.2%) | 8 (13.3%) |
| Activity of 68Ga-PSMA-HBED-CC [MBq] (mean, range) | 190.43 (87–293) | 197.50 (100–293) | 192.07 (94–293) | 186.85 (87–286) |
